UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 86

Sortiert nach

The Clinical Pharmacokinetics of Phosphodiesterase-5 Inhibitors for Erectile Dysfunction

Journal of clinical pharmacology, 2005-09, Vol.45 (9), p.987-1003

2005

Volltextzugriff (PDF)

Open Systems Pharmacology Community—An Open Access, Open Source, Open Science Approach to Modeling and Simulation in Pharmaceutical Sciences

CPT: pharmacometrics and systems pharmacology, 2019-12, Vol.8 (12), p.878-882

2019

Volltextzugriff (PDF)

LaTeX tutorial for the standardization and automation of population analysis reports

CPT: pharmacometrics and systems pharmacology, 2021-11, Vol.10 (11), p.1310-1322

2021

Volltextzugriff (PDF)

Phase I Study of the Humanized Antiepidermal Growth Factor Receptor Monoclonal Antibody EMD72000 in Patients With Advanced Solid Tumors That Express the Epidermal Growth Factor Receptor

Journal of clinical oncology, 2004-01, Vol.22 (1), p.175-184

2004

Volltextzugriff (PDF)

Safety of Hydroxocobalamin in Healthy Volunteers in a Randomized, Placebo-Controlled Study

Clinical toxicology (Philadelphia, Pa.), 2006-01, Vol.44 (S1), p.17-28

2006

Volltextzugriff (PDF)

Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanoma

Journal of translational medicine, 2009-07, Vol.7 (1), p.68-68, Article 68

2009

Volltextzugriff (PDF)

Sutimlimab Pharmacokinetics and Pharmacodynamics in Patients with Cold Agglutinin Disease

The Journal of pharmacology and experimental therapeutics, 2023-08, Vol.386 (2), p.143

2023

Volltextzugriff (PDF)

Investigation of sarizotan's impact on the pharmacokinetics of probe drugs for major cytochrome P450 isoenzymes : A combined cocktail trial

European journal of clinical pharmacology, 2006-04, Vol.62 (4), p.277-284

2006

Volltextzugriff (PDF)

Metabolism and disposition of the αv-integrin ß3/ß5 receptor antagonist cilengitide, a cyclic polypeptide, in humans

Journal of clinical pharmacology, 2015-07, Vol.55 (7), p.815-824

2015

Volltextzugriff (PDF)

Safety, tolerability, and pharmacokinetics of the novel αv-integrin antibody EMD 525797 (DI17E6) in healthy subjects after ascending single intravenous doses

Investigational new drugs, 2014-04, Vol.32 (2), p.347-354

2014

Volltextzugriff (PDF)

Population Pharmacokinetics of Cetuximab in Patients With Squamous Cell Carcinoma of the Head and Neck

Journal of clinical pharmacology, 2008-03, Vol.48 (3), p.267-278

2008

Volltextzugriff (PDF)

Metabolism and disposition of the [alpha]v-integrin ß3/ß5 receptor antagonist cilengitide, a cyclic polypeptide, in humans

Journal of clinical pharmacology, 2015-07, Vol.55 (7), p.815

2015

Volltextzugriff (PDF)

Comparative Performance of Cell Life Span and Cell Transit Models for Describing Erythropoietic Drug Effects

The AAPS journal, 2011-12, Vol.13 (4), p.650-661

2011

Volltextzugriff (PDF)

Safety, tolerability, and pharmacokinetics of the novel [alpha]v-integrin antibody EMD 525797 (DI17E6) in healthy subjects after ascending single intravenous doses

Investigational new drugs, 2014-04, Vol.32 (2), p.347

2014

Volltextzugriff (PDF)

Abstract 1296: Safety, tolerability, and pharmacokinetics of the novel αv-integrin antibody DI17E6 in healthy subjects after ascending single intravenous doses

Cancer research (Chicago, Ill.), 2011-04, Vol.71 (8_Supplement), p.1296-1296

2011

Volltextzugriff (PDF)

Tu1405 The Kappa-Opioid Receptor Agonist Asimadoline Remains Peripherally Restricted at Supra-Therapeutic Plasma Exposures

Gastroenterology (New York, N.Y. 1943), 2012-05, Vol.142 (5), p.S-824-S-824

2012

Volltextzugriff (PDF)

Changes in blood pressure after administration of hydroxocobalamin: Relationship to changes in plasma cobalamins-(III) concentrations in healthy volunteers

Clinical toxicology (Philadelphia, Pa.), 2008-07, Vol.46 (6), p.551-559

2008

Volltextzugriff (PDF)

Population pharmacokinetics of cilengitide in adult and pediatric cancer patients from a nonlinear mixed-effects analysis

Journal of clinical pharmacology, 2014-12, Vol.54 (12), p.1391-1399

2014

Volltextzugriff (PDF)

Pharmacokinetic profile of cetuximab (Erbitux™) alone and in combination with irinotecan in patients with advanced EGFR-positive adenocarcinoma

European journal of cancer (1990), 2005-08, Vol.41 (12), p.1739-1745

2005

Volltextzugriff (PDF)

Refinement of the Population Pharmacokinetic Model for the Monoclonal Antibody Matuzumab: External Model Evaluation and Simulations

Clinical pharmacokinetics, 2009-01, Vol.48 (7), p.477-487

2009

Volltextzugriff (PDF)

Abstract B214: Use of a pharmacokinetic model derived from early clinical studies to assess the relevance of covariates on cilengitide pharmacokinetics

Molecular cancer therapeutics, 2009-12, Vol.8 (12_Supplement), p.B214-B214

2009

Volltextzugriff (PDF)

Safety, pharmacokinetics, and biological pharmacodynamics of the immunocytokine EMD 273066 (huKS-IL2): results of a phase I trial in patients with prostate cancer

Journal of immunotherapy (1997), 2004-05, Vol.27 (3), p.232

2004

Volltextzugriff (PDF)

Investigation of the impact of sarizotan on the pharmacokinetics of levodopa

Biopharmaceutics & drug disposition, 2007-10, Vol.28 (7), p.339-347

2007

Volltextzugriff (PDF)

Clinical trial with escalating doses of the antiepidermal growth factor receptor humanized monoclonal antibody EMD 72 000 in patients with advanced squamous cell carcinoma of the larynx and hypopharynx

Cancer chemotherapy and pharmacology, 2001-06, Vol.47 (6), p.519-524

2001

Volltextzugriff (PDF)

1 – 25 von 86

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(76)
Mit Volltextzugriff
(72)

Publikationsform

Artikel
(82)
Buchkapitel
(4)

Sprache

Englisch
(82)
Japanisch
(11)
Deutsch
(4)

Erscheinungsjahr

n.n

Thema

Science & Technology
(54)
Life Sciences & Biomedicine
(51)
Humans
(44)
Male
(29)
Biological And Medical Sciences
(28)
Medical Sciences
(28)
Adult
(25)
Female
(18)
Pharmacology & Pharmacy
(18)
Middle Aged
(17)
Oncology
(17)
Sarcoma, Ewing - Genetics
(15)
Adolescent
(12)
Pharmacokinetics
(12)
Aged
(11)
Oncogene Proteins, Fusion - Genetics
(11)
Animals
(9)
Bone Neoplasms - Genetics
(9)
Diseases Of The Osteoarticular System
(9)
Pharmacology. Drug Treatments
(9)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

The Clinical Pharmacokinetics of Phosphodiesterase-5 Inhibitors for Erectile Dysfunction

Open Systems Pharmacology Community—An Open Access, Open Source, Open Science Approach to Modeling and Simulation in Pharmaceutical Sciences

LaTeX tutorial for the standardization and automation of population analysis reports

Phase I Study of the Humanized Antiepidermal Growth Factor Receptor Monoclonal Antibody EMD72000 in Patients With Advanced Solid Tumors That Express the Epidermal Growth Factor Receptor

Safety of Hydroxocobalamin in Healthy Volunteers in a Randomized, Placebo-Controlled Study

A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer

Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanoma

Sutimlimab Pharmacokinetics and Pharmacodynamics in Patients with Cold Agglutinin Disease

Investigation of sarizotan's impact on the pharmacokinetics of probe drugs for major cytochrome P450 isoenzymes : A combined cocktail trial

Metabolism and disposition of the αv-integrin ß3/ß5 receptor antagonist cilengitide, a cyclic polypeptide, in humans

Safety, tolerability, and pharmacokinetics of the novel αv-integrin antibody EMD 525797 (DI17E6) in healthy subjects after ascending single intravenous doses

Population Pharmacokinetics of Cetuximab in Patients With Squamous Cell Carcinoma of the Head and Neck

Metabolism and disposition of the [alpha]v-integrin ß3/ß5 receptor antagonist cilengitide, a cyclic polypeptide, in humans

Comparative Performance of Cell Life Span and Cell Transit Models for Describing Erythropoietic Drug Effects

Safety, tolerability, and pharmacokinetics of the novel [alpha]v-integrin antibody EMD 525797 (DI17E6) in healthy subjects after ascending single intravenous doses

Abstract 1296: Safety, tolerability, and pharmacokinetics of the novel αv-integrin antibody DI17E6 in healthy subjects after ascending single intravenous doses

Tu1405 The Kappa-Opioid Receptor Agonist Asimadoline Remains Peripherally Restricted at Supra-Therapeutic Plasma Exposures

Changes in blood pressure after administration of hydroxocobalamin: Relationship to changes in plasma cobalamins-(III) concentrations in healthy volunteers

Population pharmacokinetics of cilengitide in adult and pediatric cancer patients from a nonlinear mixed-effects analysis

Pharmacokinetic profile of cetuximab (Erbitux™) alone and in combination with irinotecan in patients with advanced EGFR-positive adenocarcinoma

Refinement of the Population Pharmacokinetic Model for the Monoclonal Antibody Matuzumab: External Model Evaluation and Simulations

Abstract B214: Use of a pharmacokinetic model derived from early clinical studies to assess the relevance of covariates on cilengitide pharmacokinetics

Safety, pharmacokinetics, and biological pharmacodynamics of the immunocytokine EMD 273066 (huKS-IL2): results of a phase I trial in patients with prostate cancer

Investigation of the impact of sarizotan on the pharmacokinetics of levodopa

Clinical trial with escalating doses of the antiepidermal growth factor receptor humanized monoclonal antibody EMD 72 000 in patients with advanced squamous cell carcinoma of the larynx and hypopharynx

Suchergebnisse filtern